Royalty Pharma Future Growth
Future criteria checks 3/6
Royalty Pharma is forecast to grow earnings and revenue by 6.3% and 7.2% per annum respectively. EPS is expected to grow by 5.4% per annum. Return on equity is forecast to be 22.8% in 3 years.
Key information
6.3%
Earnings growth rate
5.4%
EPS growth rate
Pharmaceuticals earnings growth | 21.5% |
Revenue growth rate | 7.2% |
Future return on equity | 22.8% |
Analyst coverage | Good |
Last updated | 18 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,093 | 1,285 | 3,019 | 3,599 | 7 |
12/31/2025 | 2,872 | 1,110 | 2,721 | 3,303 | 7 |
12/31/2024 | 2,650 | 634 | 2,620 | 3,173 | 7 |
9/30/2024 | 2,266 | 1,145 | -212 | 2,799 | N/A |
6/30/2024 | 2,238 | 673 | 401 | 2,669 | N/A |
3/31/2024 | 2,239 | 799 | 1,019 | 2,619 | N/A |
12/31/2023 | 2,355 | 1,135 | 872 | 2,988 | N/A |
9/30/2023 | 2,324 | 184 | 1,422 | 2,785 | N/A |
6/30/2023 | 2,361 | 255 | 522 | 2,750 | N/A |
3/31/2023 | 2,359 | 332 | 374 | 2,718 | N/A |
12/31/2022 | 2,237 | 43 | 402 | 2,144 | N/A |
9/30/2022 | 2,247 | 507 | 401 | 2,064 | N/A |
6/30/2022 | 2,259 | 466 | 312 | 1,995 | N/A |
3/31/2022 | 2,278 | 602 | 263 | 1,952 | N/A |
12/31/2021 | 2,289 | 620 | -174 | 2,018 | N/A |
9/30/2021 | 2,286 | 783 | -732 | 2,093 | N/A |
6/30/2021 | 2,239 | 972 | -159 | 2,132 | N/A |
3/31/2021 | 2,195 | 493 | -496 | 2,090 | N/A |
12/31/2020 | 2,122 | 495 | -148 | 2,035 | N/A |
9/30/2020 | 2,008 | 1,745 | 104 | 1,947 | N/A |
6/30/2020 | 1,934 | 1,863 | 793 | 1,858 | N/A |
3/31/2020 | 1,880 | 2,052 | 1,093 | 1,705 | N/A |
12/31/2019 | 1,814 | 2,349 | -54 | 1,667 | N/A |
12/31/2018 | 1,795 | 1,378 | 1,349 | 1,618 | N/A |
12/31/2017 | 1,598 | 1,210 | N/A | 1,418 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RPD's forecast earnings growth (6.3% per year) is above the savings rate (1%).
Earnings vs Market: RPD's earnings (6.3% per year) are forecast to grow slower than the German market (21% per year).
High Growth Earnings: RPD's earnings are forecast to grow, but not significantly.
Revenue vs Market: RPD's revenue (7.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: RPD's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RPD's Return on Equity is forecast to be high in 3 years time (22.8%)